Sanofi Pasteur makes vaccines for 20 infectious viral and bacterial diseases, such as diptheria, hepatitis A and B, meningitis, polio, tetanus, and whooping cough. It's also the world's largest maker of the dreaded flu shot, with a 40% market share. The company has more than 15 other vaccines in development, including an HIV vaccine and a combination booster shot to protect against six childhood diseases. Sanofi Pasteur has manufacturing facilities across France and the US, as well as in Argentina, Canada, China, and Thailand. The company is a subsidiary of pharmaceutical giant Sanofi-Aventis.

Laboratorios Farmacéuticos ROVI manufactures and sells pharmaceuticals in Spain and the rest of Europe. Its best selling prescription drugs include Hibor, (a brand name heparin used to prevent blood clots during surgery), osteoporosis drug Osseor, and angina drug Corlentor. ROVI's handful of OTC products include Autan insect repellant and the Enerzona line of dietary wellness products.In 2009 the company licensed Novavax's VLP vaccine technology which it will use to create a flu vaccine for the Spanish government. The E60 million ($84 million) program is being sponsored by the Spanish Ministry of Health. ROVI was founded in 1946 and went public on the Spanish Stock Exchange in late 2007.

Elixir Pharmaceuticals concocts treatments targeting metabolic diseases and disorders. Dedicated to the discovery, development, and commercialization of treatments for such diseases as diabetes and obesity, the company has taken a dual approach to its work: licensing products from other pharmaceutical companies for development and pursuing proprietary products. Product candidates currently under development include Glinsuna and Metgluna as treatment for type 2 diabetes and a ghrelin antagonist as a treatment for a range of metabolic disorders (all in phase III testing). The company is also exploring the use of sirtuin modulators to treat metabolic disorders, cancer, and neurodegenerative disease.

Cubist was founded in 1992 and is headquartered in Lexington, Massachusetts. Cubist Pharmaceuticals, Inc. operates as a biopharmaceutical company focused on the research, development, and commercialization of pharmaceutical products that address unmet medical needs in the acute care environment. The company markets CUBICIN (daptomycin for injection), the first antibiotic in a new class of anti-infectives called lipopeptides in the United States. It began promoting MERREM I.V. (meropenem for injection) in the U.S. in July 2008. MERREM is an established spectrum antibiotic developed by AstraZeneca. The Cubist product pipeline includes ecallantide, a recombinant human protein in Phase 2 clinical trials; CONSERV-1 and CONSERV-2 for the reduction of blood loss during cardiac surgery; and two Phase 1 programs that address unmet medical needs, one in CDAD (Clostridium difficile-associated diarrhea) and the other in multi-drug resistant (MDR) Gram-negative infections. In addition, the company, in collaboration with Alnylam Pharmaceuticals, Inc., has a pre-IND and a Phase 2 program underway in novel treatments for respiratory syncytial virus infections using Alnylam's RNA-interference technology.

Jamieson Laboratories, founded in 1922, manufactures and sells vitamin, multivitamin, and mineral formulations, as well as nutritional food supplements, cosmetics and skin care products, sports nutritionals, home remedy supplements, and diet and digestive formulations. Products may be purchased through health-food, nutrition, and other specialty retailers around Canada. The company also exports its products to approximately 50 countries in the Americas, Asia, Europe, the Middle East, and Africa.

BioCryst Pharmaceuticals, Inc. was founded in 1986 and is based in Birmingham, Alabama. BioCryst Pharmaceuticals, Inc. designs, optimizes, and develops small-molecule pharmaceuticals that block key enzymes involved in infectious diseases, cancer, and inflammatory diseases. It uses structure-based drug design, which incorporates multiple scientific disciplines, including biology, crystallography, medicinal chemistry, and computer modeling to develop new therapeutic candidates. The company has progressed two compounds into late-stage pivotal clinical trials comprising Peramivir, an anti-viral for influenza; and Forodesine, a purine nucleoside phosphorylase (PNP) inhibitor forcutaneous T-cell lymphoma (CTCL). Peramivir is being developed under a contract from the Biomedical Advanced Research and Development Authority (BARDA) within the United States Department of Health and Human Services (HHS).Forodesine has been granted Orphan Drug status by the FDA for three indications, including T-cell non-Hodgkin's lymphoma, including CTCL; CLL and related leukemias, such as T-cell prolymphocytic leukemia, adult T-cell leukemia, and hairy cell leukemia; and for the treatment of B-ALL. BioCryst Pharmaceuticals is also testing BCX4208, a second generation PNP inhibitor, which is in a Phase II study for the treatment of gout. The company utilizes crystallography and structure-based drug design to discover additional compounds and to progress others through pre-clinical and early development to address the unmet medical needs of patients and physicians. It has strategic alliances with the U.S. Department of Health and Human Services; Shionogi & Co., Ltd.; Green Cross Corporation; and Mundipharma International Holdings Limited.

Merck & Co., Inc. company was founded in 1891 and is headquartered in Whitehouse Station, New Jersey. Merck & Co., Inc. provides products for human and animal health primarily in the United States. The company's Pharmaceutical segment offers human health pharmaceutical products, such as therapeutic and preventive agents. Its products comprise Singulair, a leukotriene receptor antagonist for the treatment of asthma and allergic rhinitis; Cozaar, Hyzaar, Vasotec, and Vaseretic, the hypertension and/or heart failure products; Fosamax and Fosamax Plus D for treating osteoporosis; Januvia and Janumet for type 2 diabetes; Cosopt and Trusopt, the ophthalmological products; Zocor, an atherosclerosis product; Maxalt for acute migraine; Propecia to treat male pattern hair loss; Arcoxia to treat arthritis and pain; Proscar to treat symptomatic benign prostate enlargement; and Emend for the prevention of chemotherapy-induced and post-operative nausea and vomiting.Merck & Co.'s Vaccines segment comprises human health vaccines, such as preventative pediatric, adolescent, and adult vaccines. Its products include Gardasil to prevent cervical cancer, pre-cancerous and low-grade lesions, vulvar and vaginal pre-cancers, and genital warts; Varivax to prevent chickenpox; ProQuad, a pediatric combination vaccine against measles, mumps, rubella, and varicella; M-M-R II, a vaccine against measles, mumps, and rubella; RotaTeq to protect against rotavirus gastroenteritis in children; Zostavax for preventing shingles; Primaxin and Cancidas, anti-bacterial/anti-fungal products; Isentress, Crixivan, and Stocrin, antiretroviral therapies for the treatment of HIV infection; and Invanz for the treatment of infection. Merck & Co. has research, collaboration, or licensing agreements with Neuromed Pharmaceuticals, Ltd.; ARIAD Pharmaceuticals, Inc.; GTX, Inc.; Idera Pharmaceuticals; Japan Tobacco Inc.; Galapagos NV; AstraZeneca plc; Metabasis Therapeutics Inc.; Addex Pharmaceuticals Ltd.; and Nuevolution A/S.

Simcere Pharmaceutical Group was founded in 1995 and is headquartered in Nanjing, the People's Republic of China. Simcere Pharmaceutical Group is a manufacturer and supplier of branded generic pharmaceuticals in the Chinese market. The Company has introduced a generic anti-stroke medication under the brand name Bicun, a 5-FU sustained release implant under the brand name Sinofuan and an anti-cancer medication under the brand name Endu. It manufactures and sells 45 principal pharmaceutical products and is the distributor of three additional pharmaceuticals that are manufactured by independent third parties but marketed under its brand names. On May 5, 2008, it acquired 70% interest in Wuhu Zhong Ren Pharmaceutical Co., Ltd. (Wuhu Simcere Zhong Ren). On January 6, 2009, Simcere Pharmaceutical Group acquired the remaining 10% of interest of Shandong Simcere Medgenn Bio-Pharmaceutical Co., Ltd. (Shandong Simcere).

GTx, Inc. company was founded in 1997 and is headquartered Memphis, Tennessee. GTx, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of small molecules to treat cancer, osteoporosis and bone loss, muscle loss, and other serious medical conditions in the United States. It markets FARESTON tablets for the treatment of metastatic breast cancer in postmenopausal women through wholesale drug distributors. The company develops toremifene citrate, a selective estrogen receptor modulator, which completed pivotal Phase III clinical trial for the prevention of bone fractures and treatment of other estrogen deficiency side effects of androgen deprivation therapy in men with prostate cancer; and for the prevention of prostate cancer in high risk men with precancerous prostate lesions called high grade prostatic intraepithelial neoplasia (PIN), which is in pivotal Phase III clinical trial.GTx it also develops Ostarine, which completed Phase II clinical trial for the treatment of cancer cachexia; GTx-758, an oral luteinizing hormone, which is in Phase I clinical trial for the treatment of advanced prostate cancer; and MK-0773, which is in Phase II clinical trial for the treatment of sarcopenia. In addition, GTx's preclinical pipeline includes GTx-878, an estrogen receptor beta agonist. The company has strategic collaboration with Merck & Co., Inc. to discover and develop selective androgen receptor modulators; license and supply agreement with Orion Corporation to develop and commercialize products containing toremifene; and a collaboration and license agreement with Ipsen Group that provides Ipsen Group the rights to develop and commercialize toremifene in the European territory. It also has collaborations with Hybritech, Inc.; MacroArray Technologies, LLC; and Gen-Probe, Incorporated to develop an accurate blood or urine test to detect high grade PIN.

New Leaf Brands, Inc. engages in the development, marketing, and distribution of ready-to-drink (RTD) beverages. Products The company’s New Leaf brand is a natural tea sweetened with organic cane sugar and specifically formulated to address the market for a healthy but appealing beverage. New Leaf is available in 13 flavors, integrating blue teas, green teas, black teas, and white teas. New Leaf products consist of Blue Teas, such as Diet Blue Tea with Lemon, Diet Blue Tea with Peach, Blue Tea with Lemon, Blue Tea with Peach, and Blue Tea with Raspberry; Green Teas, such as Green Tea with Plum, Green Tea with Ginseng, and Green Tea with Mango; White Teas, such as White Tea with Ginseng & Honey, White Tea with Honey Dew Melon, White Tea with Strawberry, and White Tea with Tangerine; and Black Tea: Mint & Lime International Sales The company sells its New Leaf brands in Canada and the Carribean. Customers New Leaf Tea is marketed to distributors, such as natural food, gourmet food, and mainstream distributors. The company’s major distributor is Manhattan Beer. Competition The company competes with soft drink companies, such as Coca Cola, Pepsi, and Cadbury Schweppes. In addition, it competes with beverage companies, including Arizona, Snapple, Lipton Brisk, Sobe, Vitamin Water, Fuze, Nestea, Tazo, Honest Tea, and Sweet Leaf Tea. Dispositions On October 9, 2009, the company completed the sale of its nutraceutical business, Nutritional Specialties, Inc. History The company was incorporated in 1986. It was formerly known as Baywood International, Inc. and changed its name to New Leaf Brands, Inc. on October 19, 2009.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.